Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for C3MYZ5

Entry ID Method Resolution Chain Position Source
AF-C3MYZ5-F1 Predicted AlphaFoldDB

No variants for C3MYZ5

Variant ID(s) Position Change Description Diseaes Association Provenance
No variants for C3MYZ5

No associated diseases with C3MYZ5

2 regional properties for C3MYZ5

Type Name Position InterPro Accession
domain eRF1 domain 1/Pelota-like 1 - 123 IPR005140
domain eRF1 domain 3 249 - 343 IPR005142

Functions

Description
EC Number
Subcellular Localization
  • Cytoplasm
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

1 GO annotations of cellular component

Name Definition
cytoplasm The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.

2 GO annotations of molecular function

Name Definition
endonuclease activity Catalysis of the hydrolysis of ester linkages within nucleic acids by creating internal breaks.
metal ion binding Binding to a metal ion.

3 GO annotations of biological process

Name Definition
nuclear-transcribed mRNA catabolic process, no-go decay The chemical reactions and pathways resulting in the breakdown of the transcript body of a nuclear-transcribed mRNA with stalls in translation elongation.
nuclear-transcribed mRNA catabolic process, non-stop decay The chemical reactions and pathways resulting in the breakdown of the transcript body of a nuclear-transcribed mRNA that is lacking a stop codon.
RNA surveillance A process that identifies and degrades defective or aberrant RNAs.

No homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
No homologous proteins
10 20 30 40 50 60
MRILEFDEKR QAAKLHIESE DDLWILHLIL EKGDKVVAKT TRDIGLGKES RRIPMTIVLK
70 80 90 100 110 120
VDYTEFQEFT NRLRIHGIIE DAPERFGIRG AHHTINLDIG DEIIIIKQQW SKYALDKLKK
130 140 150 160 170 180
QADKRSKIII ALVDFDEYLI AIPFEQGIKI LSEKSLRSLN EEEGIIEQNA LEVATELAEY
190 200 210 220 230 240
VKQYNPDAIL LAGPGFFKEE VAKKVNNILK NKKVYIDSVS SATRAGLHEI LKRDIIDKIM
250 260 270 280 290 300
SDYEIAIGAK KMEKAMELLA KQPELVTYGL EQVKNAVEMG AVETVLLIED LLSSNNQERL
310 320 330 340
AIERILEDIE NKRGEIILVP KESPIYFELK NLTGILAILR FRIN